Skip to Main Content

Helix, the Silicon Valley company that’s styled itself as an app store for DNA tests, made a splash last week when it announced it had raised $200 million — the latest windfall for a company leveraging a boom in consumer genomics.

But as money sloshes around the industry, there’s an uneasy and unsettled question gnawing at even the most bullish investors: Are these bets going to pay off?

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED

Comments are closed.